Reviewer’s report

Title: A case of renal thrombotic microangiopathy associated with the use of Carfilzomib following autologous stem cell transplantation for multiple myeloma

Version: 2 Date: 25 May 2014

Reviewer: Riyaj Kasekar

Reviewer’s report:

• Discretionary Revisions (which are recommendations for improvement but which the author can choose to ignore) –
  1. Mention values in SI units in brackets alongside the conventional units e.g. µmol/L for serum creatinine.

• Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)
  3. Please use the subheading ‘Discussion’ between lines 164 and 165 on page 8.
  4. The abrupt rise and subsequent improvement in the proteinuria is congruent with the patient’s blood pressure control and could be solely explained by that.
  5. Page 7 line 143 – EM appearance of diffuse podocytopathy – the authors should attempt to explain this finding in the discussion as it is not typically seen in renal thrombotic microangiopathy to my understanding.

• Major Compulsory Revisions (which the author must respond to before a decision on publication can be reached).
  6. Page 7 line 150-151. Authors fail to mention whether the laboratory parameters like LDH, Haptaglobin and platelet count improved weeks after stopping the offending agent as that will make a stronger case for the association of the drug and the adverse event.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests